Skip to main content

Find Clinical Trials

Home
Conditions
Asthma

Clinical trial condition

Asthma

Explore clinical trials studying Asthma. Study availability and eligibility vary by location and protocol.

3,549 public trials 274 recruiting studies

Refine in advanced search Browse all conditions

Asthma trial results

Completed

Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve

NCT02953041

Conditions: Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations: Asthma Research Lab, University of Saskatchewan Saskatoon, Saskatchewan, Canada

View Trial Details

Completed

Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler

NCT01213849

Conditions: Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations: GSK Investigational Site London, United Kingdom

View Trial Details

Completed

The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)

NCT00777764

Conditions: Asthma, Bronchial Diseases, Healthy, +7 more
Locations: Not specified

View Trial Details

Completed

A Blinded, Dose Ascending Study to Assess the Pharmacokinetics, Safety and Tollerability of Repeat Inhaled Doses of Nebulised GW870086X in Healthy Adult Male Volunteers.

NCT01160003

Conditions: Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations: GSK Investigational Site Berlin, Germany

View Trial Details

Completed

A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)

NCT00096954

Conditions: Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations: Not specified

View Trial Details

Completed

A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)

NCT01669070

Conditions: Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations: GSK Investigational Site Groningen, Netherlands

View Trial Details

Completed

Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects

NCT01299558

Conditions: Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations: GSK Investigational Site Randwick, New South Wales, Australia

View Trial Details

Completed

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

NCT01772368

Conditions: Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations: Teva Investigational Site 10453 Denver, Colorado, United States

Teva Investigational Site 10452 North Dartmouth, Massachusetts, United States

Teva Investigational Site 10455 St Louis, Missouri, United States

Teva Investigational Site 10454 Skillman, New Jersey, United States

View Trial Details

Completed

Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol Combination

NCT01485445

Conditions: Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations: GSK Investigational Site Berlin, Germany

View Trial Details

Completed

To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)

NCT01725685

Conditions: Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations: GSK Investigational Site Baltimore, Maryland, United States

View Trial Details